

EQA round: APLA2/23 - Antiphospholipid Antibodies

Deadline: 29.9.2023

Setup: groups - measurement principle

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(465) anti-β2-glycoprotein 1 screening		13			13	11	85
Sample A		13			13	11	85
(2) EIA (ELISA)		1	7,7	Negative			
		1	7,7	Inconclusive result (borderline)			
	CVP >>>	10	77	Positive			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	7,7	Positive			
Sample B		13			13	13	100
(2) EIA (ELISA)	CVP >>>	12	92	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	7,7	Negative			
(467) anti-β2-glycoprotein 1 IgG		60			60	55	92
Sample A		60			60	56	93
(2) EIA (ELISA)		3	5	Negative			
		1	1,7	Inconclusive result (borderline)			
	CVP >>>	33	55	Positive			
(3) FIA (FEIA, TRACE)	CVP >>>	4	6,7	Positive			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	19	32	Positive			
Sample B		60			60	59	98
(2) EIA (ELISA)	CVP >>>	36	60	Negative			
		1	1,7	Positive			
(3) FIA (FEIA, TRACE)	CVP >>>	4	6,7	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	19	32	Negative			
(468) anti-β2-glycoprotein 1 IgM		59			59	59	100
Sample A		59			59	59	100
(2) EIA (ELISA)	CVP >>>	36	61	Negative			
(3) FIA (FEIA, TRACE)	CVP >>>	4	6,8	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	18	31	Negative			
(99) Another measurement principle	CVP >>>	1	1,7	Negative			
Sample B		59			59	59	100
(2) EIA (ELISA)	CVP >>>	36	61	Negative			
(3) FIA (FEIA, TRACE)	CVP >>>	4	6,8	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	18	31	Negative			
(99) Another measurement principle	CVP >>>	1	1,7	Negative			
(461) anti-cardiolipin screening		15			15	15	100
Sample A		15			15	15	100
(2) EIA (ELISA)	CVP >>>	14	93	Positive			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	6,7	Positive			
Sample B		15			15	15	100
(2) EIA (ELISA)	CVP >>>	14	93	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	6,7	Negative			
(463) anti-cardiolipin IgG		65			65	62	95
Sample A		65			65	63	97
(2) EIA (ELISA)		2	3,1	Negative			
	CVP >>>	38	58	Positive			
(3) FIA (FEIA, TRACE)	CVP >>>	4	6,2	Positive			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	20	31	Positive			
(99) Another measurement principle	CVP >>>	1	1,5	Positive			
Sample B		65			65	64	98
(2) EIA (ELISA)	CVP >>>	39	60	Negative			
		1	1,5	Positive			
(3) FIA (FEIA, TRACE)	CVP >>>	4	6,2	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	20	31	Negative			
(99) Another measurement principle	CVP >>>	1	1,5	Negative			
(464) anti-cardiolipin IgM		64			64	64	100
Sample A		64			64	64	100
(2) EIA (ELISA)	CVP >>>	40	63	Negative			
(3) FIA (FEIA, TRACE)	CVP >>>	4	6,3	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	20	31	Negative			
Sample B		64			64	64	100
(2) EIA (ELISA)	CVP >>>	40	63	Negative			
(3) FIA (FEIA, TRACE)	CVP >>>	4	6,3	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	20	31	Negative			